An oral, brain-penetrant NLRP3 inhibitor produced an 85%+ median drop in hsCRP at clinically practical doses. For the inflammaging thesis the site is built on, this is the cleanest pharmacological validation we have seen this year.
BioAge Labs reported topline Phase 1 results on April 21, 2026 for BGE-102, its oral, brain-penetrant NLRP3 inhibitor. The headline number caught the field's attention: at both 120 mg and a newly added 60 mg once-daily dose, median hsCRP — a standard marker of systemic inflammation — fell by at least 85% in obese participants with elevated baseline inflammation. The drug was well tolerated across the doses tested.
NLRP3 is a sensor that helps assemble the inflammasome — a multiprotein machine inside immune cells that triggers the release of pro-inflammatory cytokines like IL-1β. In youthful immune function, NLRP3 fires in response to genuine threats and then resolves. In aging, the inflammasome becomes chronically over-active, contributing to inflammaging — the chronic, low-grade inflammation we cover at length elsewhere on the site. Inflammaging is itself implicated in cardiovascular disease, neurodegeneration, type 2 diabetes, and the broader decline in immune fitness with age.
An oral NLRP3 blocker with a clean safety profile and a strong hsCRP signal is exactly the molecule shape geroscience has been waiting for. Injectable anti-IL-1 drugs already exist for narrow indications, but they're impractical for chronic preventive use. A once-daily pill that reproduces the anti-inflammatory effect — without the injection burden — is a different proposition.
The trial enrolled adults with obesity and elevated baseline hsCRP. Across the 120 mg and 60 mg once-daily cohorts, median hsCRP dropped by ≥85%. BioAge framed BGE-102 as a potential best-in-class oral NLRP3 inhibitor with the anti-inflammatory efficacy historically associated with injectables. The company has paired the Phase 1 data with a follow-up: a Phase 1b/2a in diabetic macular edema is planned to start mid-2026, with readout expected in 2027.
Phase 1 trials are small, short, and primarily about safety and pharmacology. A large drop in hsCRP is a meaningful biomarker signal, but it is not the same as a demonstrated clinical benefit — for cardiovascular outcomes, cognitive endpoints, or longevity-relevant hard endpoints. The next trials matter more.
For readers who use our Lab Results Interpreter and our bloodwork guide, hsCRP is one of the standard markers we flag for tracking. The drug isn't available, but the data adds confidence to the broader inflammaging thesis the site is built on: that chronic low-grade inflammation is a tractable target, not a passive consequence of aging. The interventions we cover with the strongest current evidence — exercise (especially Zone 2), sleep, omega-3 adequacy, body-composition management — already act on this pathway. BGE-102 represents a pharmacological complement to that lifestyle stack, not a replacement.
The DME (diabetic macular edema) trial is the immediate near-term readout. The bigger longevity-relevant question is whether BioAge or a competitor will push NLRP3 inhibition toward an atherosclerotic-cardiovascular-disease indication, where the trial machinery is well-established and hsCRP reduction has the most established disease-modifying link. The Phase 1 hsCRP signal sets up that conversation; the next two years of trial design will reveal whether BioAge actually pursues it.